

Phase III adjuvant trial in pancreatic cancer comparing 5-Fluorouracil (5FU) and D-L-folinic acid versus gemcitabine versus no adjuvant treatment

Submission date 01/07/2001	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 01/07/2001	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 28/10/2021	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00058201

Secondary identifying numbers

ESPAC-3

Study information

Scientific Title

Phase III adjuvant trial in pancreatic cancer comparing 5-Fluorouracil (5FU) and D-L-folinic acid versus gemcitabine versus no adjuvant treatment

Acronym

ESPAC-3

Study objectives

Not provided at time of registration

Please note that as of 03/09/09 the ethics and primary outcomes of this trial were updated. The end date of this trial was also extended from 01/12/2005 to 07/05/2008

Ethics approval required

Old ethics approval format

Ethics approval(s)

Added 03/09/09: Received from local medical ethics committee (MREC ref: 99/8/74)

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Pancreatic cancer

Interventions

1. 5-FU and Folinic Acid: Folinic Acid D-L form: 20 mg/m² iv bolus injection followed by 5-FU: 425 mg/m² iv bolus injection given on 5 consecutive days every 28 days for six cycles (24 weeks)
2. Gemcitabine: 1000 mg/m² given as iv infusion over 30 min once a week for 3 of every 4 weeks for six cycles (24 weeks)
3. No adjuvant

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

5-Fluorouracil (5FU), D-L-folinic acid, gemcitabine

Primary outcome measure

Added 03/09/09:

1. Survival at 2 and 5 years
2. Toxicity
3. Quality of life
4. Relapse free survival

Secondary outcome measures

Not provided at time of registration

Overall study start date

03/07/2000

Completion date

07/05/2008

Eligibility**Key inclusion criteria**

- 1.1. Patients who have undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas
- 1.2. Patients with other cancer may be included who have had complete macroscopic resection for unusual malignancies of the pancreas; cancer of the periampullary region; cancer of the intra-pancreatic bile duct; periampullary cancer of uncertain origin
2. Histological confirmation of the primary diagnosis
3. Histological examination of all resection margins
4. No evidence of malignant ascites, liver metastases, spread to other distant abdominal organs, peritoneal metastases, spread to extra-abdominal regions
5. A World Health Organisation (WHO) performance status ≤ 2
6. Fully recovered from surgery and fit to take part in the trial. Life expectancy of more than 3 months
7. Able to attend for administration of adjuvant therapy
8. Able to attend for long-term follow-up
9. No previous or concurrent malignancy diagnoses
10. No serious medical or psychological condition precluding adjuvant treatment
11. Fully informed written consent given

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

Not provided at time of registration

Key exclusion criteria

Does not match inclusion criteria

Date of first enrolment

03/07/2000

Date of final enrolment

07/05/2008

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

Sponsor details

PO Box 123

Lincoln's Inn Fields

London

United Kingdom

WC2A 3PX

+44 (0)207 317 5186

kate.law@cancer.org.uk

Sponsor type

Charity

Website

<http://www.cancer.org.uk>

ROR

<https://ror.org/054225q67>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK (CRUK) (UK)

Alternative Name(s)

CR_UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	08/09/2010		Yes	No

Results article	results	11/07/2012		Yes	No
Results article	results	01/01/2014		Yes	No
Results article	results	20/02/2014		Yes	No
Plain English results			28/10/2021	No	Yes